Research Team

Aydin Huseynov, M.D., CFA

Managing Director, Biotechnology Equity Research

Dr. Huseynov is an Equity Research Analyst covering Biotechnology companies. Prior to joining Ladenburg, he was Managing Director, Senior Equity Research Analyst at Benchmark Company, LLC, covering large-, mid-, and small-cap biotech companies. Before Benchmark, Dr. Huseynov worked on the Biotechnology Equity Research team at Oppenheimer & Co. Inc. Prior to Oppenheimer, he worked as a strategy consultant at Syneos Health Consulting where he advised biopharma companies in R&D, clinical, commercial, valuation, and market access projects, and as a corporate strategist at Teva Pharmaceuticals. Earlier in his career, he was a practicing physician and entrepreneur. Dr. Huseynov holds an MBA degree from The Fuqua School of Business, Duke University, an M.D. from Azerbaijan Medical University, and an MS in International Economic Relations from Khazar University. He is a CFA Charterholder.      

Healthcare & Life Sciences

Matthew L. Kaplan

Matthew L. Kaplan

Managing Director, Head of Healthcare Equity Research

Jeffrey S. Cohen

Jeffrey S. Cohen

Managing Director, Equity Research

Michael J. Higgins

Michael J. Higgins

Managing Director, Senior Biopharmaceuticals Equity Research

Ahu Demir, Ph.D

Ahu Demir, Ph.D

Equity Research, Biotechnology

Aydin Huseynov, M.D., CFA

Aydin Huseynov, M.D., CFA

Managing Director, Biotechnology Equity Research

Yield-Oriented Equities

Mickey M. Schleien, CFA

Mickey M. Schleien, CFA

Managing Director, Equity Research

Christopher Nolan, CFA

Christopher Nolan, CFA

Executive Vice President, Equity Research

Telecom, Media & Technology

Jon R. Hickman

Jon R. Hickman

Managing Director, Equity Research

Glenn G. Mattson, Jr.

Glenn G. Mattson, Jr.

Vice President, Equity Research